FDA Updates SMA Treatment Dosing - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

  • By

  • Kathryn Wighton

  • March 30, 2026

  • 2 min

Share

  • 1

    The FDA approved a higher-dose regimen of nusinersen (SPINRAZA) for spinal muscular atrophy in pediatric and adult patients.

  • 2

    The new dosing schedule includes two 50 mg loading doses followed by maintenance doses of 28 mg every 4 months.

  • 3

    Approval was based on the phase 2/3 DEVOTE study, which showed significant motor function improvement in treatment-naïve infants.

  • 4

    The safety profile of the high-dose regimen aligns with the lower-dose regimen, with common adverse events including pneumonia.

  • 5

    Nusinersen is delivered via intrathecal injection and is expected to be available in the US soon, following approvals in other regions.

Original Source(s)

FDA Updates SMA Treatment Dosing

  • by Kathryn Wighton

  • March 30, 2026

Related Content

Sedative medications: a potentially modifiable risk factor for improving neurocognitive outcomes after critical illness in infants and children

Volatility priors may reveal delusion severity in schizophrenia

Expectations of environmental instability declined alongside delusional symptoms during 6 months following an acute psychotic episode.

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.